Literature DB >> 3001806

Tolerance to the benzodiazepine diazepam in an animal model of anxiolytic activity.

D N Stephens, H H Schneider.   

Abstract

The antipunishment properties of diazepam (DZP) were investigated in mice treated acutely, or following nine daily treatments with either DZP (5 mg/kg, PO) or its vehicle. Acutely, or following chronic vehicle treatment, DZP produced a dose-related increase in activity punished by footshock. Following chronic DZP, test doses of DZP given 24 or 48 h following the last chronic treatment were no longer, or less effective in enhancing punished activity. Effects on unpunished activity were unaffected. In a study of the time course of tolerance development, tolerance was not seen after one or three daily treatments but was present after 6 days. Following establishment of tolerance by 9 days' treatment, the antipunishment activity of DZP reappeared after 8 days' withdrawal and was restored to acute levels after 16 days. Tolerance was not associated with changes in benzodiazepine (BZ) receptor affinity or numbers, but the ability of GABA to enhance BZ binding was increased. There was no change in the ability of DZP or the convulsant beta-carboline DMCM to modulate 35S-TBPS binding. The mechanism of tolerance to the antipunishment properties of DZP therefore remains unknown.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3001806     DOI: 10.1007/bf00432715

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  GABAergic modulation of benzodiazepine binding site sensitivity.

Authors:  J F Tallman; J W Thomas; D W Gallager
Journal:  Nature       Date:  1978-07-27       Impact factor: 49.962

Review 2.  Molecular mechanisms in the receptor action of benzodiazepines.

Authors:  E Costa; A Guidotti
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

3.  Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam.

Authors:  D L Margules; L Stein
Journal:  Psychopharmacologia       Date:  1968

4.  A new method for rapid screening of minor tranquillizers in mice.

Authors:  J R Boissier; P Simon; C Aron
Journal:  Eur J Pharmacol       Date:  1968-09       Impact factor: 4.432

5.  Rapid development of tolerance to the sedative effects of lorazepam and triazolam in rats.

Authors:  S E File
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Changes in regional concentrations in the rat brain of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid during the development of tolerance to the sedative action of chlordiazepoxide.

Authors:  R G Lister; S E File
Journal:  J Pharm Pharmacol       Date:  1983-09       Impact factor: 3.765

7.  Differential modulation of [35S]TBPS binding by the occupancy of benzodiazepine receptors with its ligands.

Authors:  P Supavilai; M Karobath
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

8.  Facilitation of benzodiazepine binding by sodium chloride and GABA.

Authors:  I L Martin; J M Candy
Journal:  Neuropharmacology       Date:  1978-11       Impact factor: 5.250

9.  Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain.

Authors:  C D Wise; B D Berger; L Stein
Journal:  Science       Date:  1972-07-14       Impact factor: 47.728

10.  Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate.

Authors:  D J Greenblatt; R I Shader; J S Harmatz; A Georgotas
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

View more
  9 in total

1.  Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models.

Authors:  M Bourin; M Hascoet; B Mansouri; M C Colombel; J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

2.  Decreased expression of gamma-aminobutyric acid type A/benzodiazepine receptor beta subunit mRNAs in brain of flurazepam-tolerant rats.

Authors:  T J Zhao; T H Chiu; H C Rosenberg
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

3.  Changes in benzodiazepine/GABA receptor complex function in benzodiazepine-tolerant mice.

Authors:  D J Nutt; S C Taylor; H J Little; B L Standing; R G Gale
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3'-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine. 2. Evaluation of its tolerance and dependence producing potential and of its effects on benzodiazepine withdrawal in the elevated plus-maze test in rats.

Authors:  P Chopin; M B Assié; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment.

Authors:  R R Brett; J A Pratt
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

6.  Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies.

Authors:  G H Jones; C Schneider; H H Schneider; J Seidler; B J Cole; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

Review 7.  Animal models of drug withdrawal symptoms.

Authors:  M W Emmett-Oglesby; D A Mathis; R T Moon; H Lal
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Learnt tolerance to sedative effects of chlordiazepoxide on self-stimulation performance, but no tolerance to facilitatory effects after 80 days.

Authors:  L J Herberg; A M Montgomery
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  The use of imepitoin (Pexion™) on fear and anxiety related problems in dogs - a case series.

Authors:  Kevin J McPeake; Daniel S Mills
Journal:  BMC Vet Res       Date:  2017-06-13       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.